

#### **INSTITUTIONAL BIOSAFETY COMMITTEE**

Tuesday, 08/19/2025 12:04 PM MSBII 5A116

### Chairperson

Mingtao Zeng, PhD

# **Board Members**

Anthony W Baird, DSc Jeana E. Barrow, DVM Huanyu Dou, MD Pallavi Dubey, PhD Ivan E Flores, BS Daniel Gonzales, BA Sehrish Javaid. PhD

# **Administrative Staff**

Amanda Ortiz Myrna Arvizo

# **MEMBERS PRESENT**

Anthony W Baird, DSc, Jeana E. Barrow, DVM, Huanyu Dou, MD, Pallavi Dubey, PhD, Ivan E Flores, BS, Daniel Paul Gonzales, BMS, Sehrish Javaid, BDS, MS, PhD

# MEMBERS ABSENT

Mingtao Zeng, PhD

#### STAFF PRESENT

Barbara S Castellanos, M.S., Amanda Ortiz

#### **GUESTS PRESENT**

N/A

# CALL TO ORDER

Anthony Baird, DSc called the meeting to order at 12:03 p.m. Quorum is 5 members. 6 members are present at the call to order, including scientific, non-scientific and non-affiliated members. 6 members present at conclusion.

All proceedings and discussion in the upcoming meeting are confidential and should not be discussed outside of the meeting. Additionally, any member who has a conflict of interest that would preclude making an objective determination about a study should recuse him/herself from voting on the study.

A draft of the meeting minutes from 07/15/2025 was distributed for review on 07/17/2025. There were no controversial entries or objections. A motion to approve the meeting minutes as written was made by DG and

TTUHSC EP IBC Meeting Minutes - 08/19/2025

Page **1** of **2** 



seconded by JB. The committee voted unanimously to approve the minutes.

The meeting was adjourned at 12:49 p.m.

**MISCELLANEOUS** 

N/A

# **3-YEAR RENEWALS**

IBC# 22010 Full Renewal Expiration Date: 08/31/2025

Umadevi Kandalam, PhD/TTUHSC El Paso - SOD - School of Dentistry

Biosafety Level: BSL 2

#### **ADMINISTRATIVE COMMENT:**

# **Comment:**

The PI has responded to the concerns of the reviewers. The stipulations addressed were:

- 1. In the Study Application, section 5.3, enter a bay letter after 4B406
- 2. A research financial disclosure form must be completed for Meredith Reinhardt, Denyse Salazar, and Todd Parco
- 3. In section 6.4, there seems to be a discrepancy in the information for bup/bupSR in the chart. The concentration of the drugs and the max amount kept do not make sense in this context. Please revise. Reach out for assistance if needed. 4. In section 9.2, is there truly no hazard involved in handling these human cell lines? Consider adding reference to possible bloodborne pathogens associated with human cells/fluids.

### **MEMBER COMMENTS**:

### Comment:

In section 6.4, this controlled substances chart still has errors - In the concentration column, this should be the mg/mL amount stated on the bottle. Your buprenorphine HCl will vary depending on the manufacturer. If you are using EthiqaXR, this will be 1.3mg/mL. If you are using a compounded version of buprenorphineSR, this will vary; check what is written on your bottles. In the max quantity expected in the lab column, this should be a volume, probably in mL, depending on how many bottles you plan to have in your laboratory at one time. The volume of each bottle is on the label. If you are using EthiqaXR, and plan to only have one bottle at a time, this will be 3mL, for example.

### Comment:

Cell lines have been added with appropriate safety measures implemented. Several other drug-related stipulations were requested and have been addressed by the PI.

**RECOMMENDATIONS:** Approval Pending Minor Modification

**STIPULATIONS:** 1. In section 6.4, this controlled substances chart still has errors - In the concentration column, this should be the mg/mL amount stated on the bottle. Your buprenorphine HCl will vary depending on the manufacturer. If you are using EthiqaXR, this will be 1.3mg/mL. If you are using a compounded version of buprenorphineSR, this will vary; check what is written on your bottles. In the max quantity expected in the lab column, this should be a volume, probably in mL, depending on how many bottles you plan to have in your laboratory at one time. The volume of each bottle is on the label. If you are using EthiqaXR, and plan to only have one bottle at a time, this will be 3mL, for example.

**MOTION AND VOTE**: The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed the 3-year renewal at their full board meeting and determined that additional information or modifications are required prior to approval of this protocol. Total Members Voting: **7** [ For: **6** Absent: **1** Against: **0** Conflict of Interest: **0** Not Present: **0** Abstained: **0** ]

SUBMISSION OUTCOME: Additional Information Required

TTUHSC EP IBC Meeting Minutes - 08/19/2025

Page **1** of **2** 



IBC# 22010 Full Renewal Expiration Date: 08/31/2025

Umadevi Kandalam, PhD/TTUHSC El Paso - SOD - School of Dentistry

Biosafety Level: BSL 2

#### **ADMINISTRATIVE COMMENT:**

# Comment:

This is a Three Year Renewal. The PI is requesting continued use of

Space: MSB II 4B406

Biological Agents: Cell Lines

Chemicals: N/A Biosafety Level: 2

This study does require On Campus Transport training. The PI and staff are current on LSE, COI, and FD.

This protocol does not involve recombinant or synthetic nucleic acid molecules.

Stipulations have been added

# **MEMBER COMMENTS:**

# **Comment:**

In section 6.4, there seems to be a discrepancy in the information for bup/bupSR in the chart. The concentration of the drugs and the max amount kept do not make sense in this context. Please revise. Reach out for assistance if needed.

In section 9.2, is there truly no hazard involved in handling these human cell lines? Consider adding reference to possible bloodborne pathogens associated with human cells/fluids.

# Comment:

Location and chemical/biologicals approved by Safety Services.4. Pending drug amount stipulation/discussion and possible addition of blood borne pathogen risk. Transport training confirmation is required, and other safety requirements and space appear to be appropriate for this risk level.

**RECOMMENDATIONS:** Additional Information Required

STIPULATIONS: 1. In the Study Application, section 5.3, enter a bay letter after 4B406

- 2. A research financial disclosure form must be completed for Meredith Reinhardt, Denyse Salazar, and Todd Parco
- 3. In section 6.4, there seems to be a discrepancy in the information for bup/bupSR in the chart. The concentration of the drugs and the max amount kept do not make sense in this context. Please revise. Reach out for assistance if needed.
- 4. In section 9.2, is there truly no hazard involved in handling these human cell lines? Consider adding reference to possible bloodborne pathogens associated with human cells/fluids.

SUBMISSION OUTCOME: Additional Information Required

IBC# 22009 Full Renewal Expiration Date: 08/31/2028

Jeana E. Barrow, DVM/TTUHSC El Paso - OR - LARC

Biosafety Level: BSL 2

# **ADMINISTRATIVE COMMENT:**

Comment:

Protocol Type: Three Year Renewal

PI Request: Use of Space: LARC

Biological Agents: N/A

TTUHSC EP IBC Meeting Minutes - 08/19/2025

Page **1** of **2** 



Chemicals: N/A

Controlled Substances: Buprenorphine, Buprenorphine SR, Ketamine

Biosafety Level: BSL-2

Hazardous Shipping & On-Campus Transport Training: Not required

Recombinant or Synthetic Nucleic Acids: Not involved

Training Compliance: PI and all key personnel are current on required LSE, COI, and Financial Disclosure

trainings

#### **MEMBER COMMENTS:**

### Comment:

As per section 2.1, no changes to currently approved protocol. No concerns from Safety Services/Biological Safety Officer.

# **Comment:**

The protocol is linked to LARC training on handling of mice and rats in lab setting. There are no concerns that I see with the protocol, I recommend for approval.

**RECOMMENDATIONS**: Approve

**MOTION AND VOTE:** The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed this protocol at their full board meeting and granted unrestricted approval.

Total Members Voting: 7 [ For: 5 Absent: 1 Against: 0 Conflict of Interest: 1 Not Present: 0 Abstained: 0 ]

SUBMISSION OUTCOME: Approved

IBC# 22008 Full Renewal Expiration Date: 08/31/2025

Subodh Kumar, PhD/TTUHSC El Paso - SOM - MTM-CoE in Infectious Diseases

Biosafety Level: BSL 2

### **ADMINISTRATIVE COMMENT:**

#### Comment:

Protocol Type: Three Year Renewal

PI Request: Use of Space: MSB-1 3015 H

Biological Agents: Bacteria, Viruses, Body Fluids, Human Brain, Cell Lines,

Chemicals: Paraformaldehyde, Acrylamide/Bisacrylamide Solution, Isoflurane, Methanol, Chloroform,

Paraformaldehyde fixative solution, Ethidium Bromide

Controlled Substances:N/A Biosafety Level: BSL-2

Hazardous Shipping: Required

Recombinant or Synthetic Nucleic Acids: Yes

Training Compliance: PI and all key personnel are current on required LSE, COI, and Financial Disclosure trainings Safety please confirm that the PI does NOT need to include Isoflurane, methanol, and chloroform to the application.

#### **MEMBER COMMENTS:**

# **Comment:**

In section 5.5, Daniela Rodarte is listed as a lab member handling shipping of substances; she is not listed in section 3; please revise either section for consistency.

In section 9.15, how long after injection of lentiviral vectors are animals estimated to be shedding the agent? Should a cage change hold be placed on these animals during this time period to protect staff?

Section 5.5 does state lab will be shipping hazardous materials and/or biologicals. Please have proper training for shipping.

TTUHSC EP IBC Meeting Minutes - 08/19/2025

Page **1** of **2** 



Daniela Rodarte is a member of the research team and should be listed in Section 3 The PI should list Isoflurane, methanol and chloroform on the application. Each have their own hazards.

Comment:

**RECOMMENDATIONS:** Table

**STIPULATIONS:** 1. In section 5.5, Daniela Rodarte is listed as a lab member handling shipping of substances; she is not listed in section 3; please revise either section for consistency.

2. In section 9.15, how long after injection of lentiviral vectors are animals estimated to be shedding the agent? Should a cage change hold be placed on these animals during this time period to protect staff?

**MOTION AND VOTE**: The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed this protocol at their full board meeting and tabled the submission due to the need for additional information or modifications.

Total Members Voting: 7 [ For: 6 Absent: 1 Against: 0 Conflict of Interest: 0 Not Present: 0 Abstained: 0 ]

**SUBMISSION OUTCOME**: Tabled

# **AMENDMENTS**

IBC# 10010 Full Renewal Expiration Date: 07/31/2028

Mingtao Zeng, PhD/TTUHSC El Paso - SOM - MTM-CoE in Infectious Diseases

Biosafety Level: BSL 2+

# ADMINISTRATIVE COMMENT:

### Comment:

The PI is requesting to add the use of human CD34+ stem cells. The application has been revised.

# **MEMBER COMMENTS:**

### Comment:

The information about hematopoietic stem cells has been added and clarified—no further concern.

### **Comment:**

No concerns from Safety/BSO on this addition of information.

**RECOMMENDATIONS**: Approve

**MOTION AND VOTE:** The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed this protocol at their full board meeting and granted unrestricted approval.

Total Members Voting: 7 [ For: 7 Absent: 0 Against: 0 Conflict of Interest: 0 Not Present: 0 Abstained: 0 ]

**SUBMISSION OUTCOME**: Approved

# **INITIAL REVIEWS**

IBC# 25008 Full Renewal Expiration Date:

Darly Carmelle Ghislaine Mayer/TTUHSC El Paso - SOM - Medical Education

Biosafety Level: BSL 2

### **ADMINISTRATIVE COMMENT:**

# **MEMBER COMMENTS**:

#### Comment:

This is an Initial Application. The PI is requesting

Space: MEB 4100 Chemicals: N/A

Biological Agents: Fungi Biosafety Level: BSL2

Transport and hazardous shipper training will not be required

This protocol does not involve recombinant or synthetic nucleic acid molecules.

Lab Safety Essential training is pending for Dr. Mayer, Alexis H., and Emily Z. Safety assigned LSE on 7/22.

COI is pending for S.A., a notice was sent on 7/22.

If this is BSL-3 then personnel will have to be trained.

TTUHSC EP IBC Meeting Minutes - 08/19/2025

Page **1** of **2** 



# **MEMBER COMMENTS:**

### Comment:

Since the proposed research involves only collection of environmental soil samples and lab extraction of Coccidioides DNA, BSL2 or enhanced BSL2 precaution need to be enforced. "Any culturing or handling of Coccidioides spore positive samples must be performed in BSL-3 containment".

# **Comment:**

The proposal states that the work will be conducted at a BSL-2 level. But, Coccidioides spp. is classified by the CDC and NIH as a BSL-3 pathogen due to its high infectivity via aerosolized arthroconidia (spores). Performing environmental culture or spore handling at BSL-2 significantly increases the risk of laboratory-acquired infections (LAIs) and ecological contamination. Suggestion: Any culturing or handling of Coccidioides spores must be performed in BSL-3 containment.

# Comment:

When checking location for this protocol, I asked for additional information from the lab manager if there was going to be a large amount of spores or cultivating of spores. The answers were no to both questions. The experiment will be to check soil samples for the spores using DNA extraction kit and handling stops there. Lab is identified as BSL2 with equipment and PPE available. Safety agrees with other comments regarding possible use of BSL3. No other concerns from Safety Services.4. In section 5.1 - please describe what is being done and how during this study, in order to get a full picture of potential human exposure.

In section 6.1 - the protocol states no chemicals will be used, however in section 9.13, there are two boxes checked related to the usage and storage of chemicals. Please revise for consistency.

In section 9.11 - depending on the way the soil samples are collected (pending elaboration and detailing after revision to section 5.1), this activity may also generate dust and aerosols. Consider checking these boxes as well. As a previous reviewer stated, according to the CDC and NIH this is a BSL3 pathogen. According to the Pathogen Safety Data Sheet, this is a RG3 pathogen. I am torn about the classification in this instance, however. The soil samples to be handled and tested will not be cultured or amplified. I believe proper use of an N95, hood/BSC, and other PPE will reduce the risk to handlers.

# Comment:

**RECOMMENDATIONS:** 1. Additional Inforamtion Required

**STIPULATIONS:** 1. In section 5.1 - please describe what is being done and how during this study, in order to get a full picture of potential human exposure.

- 2. In section 5.1 clarify how Coccidioides will be handled. Specifically, that the agent will not be concentrated at any stage of the work and that it will only be used as described in the submitted summary. This information is important to confirm that the research poses no additional risk beyond the intended procedures.
- 3. In section 6.1 the protocol states no chemicals will be used, however in section 9.13, there are two boxes checked related to the usage and storage of chemicals. Please revise for consistency.
- 4. In section 7.1 please add the location of where the soil will be collected.
- 5. In section 9.2 please describe your disposal plan for Coccidioides, including how all waste will be decontaminated and discarded in the BSL2 lab.
- 6. In section 9.11 depending on the way the soil samples are collected (pending elaboration and detailing after revision to section 5.1), this activity may also generate dust and aerosols. Consider checking these boxes as well
- 7. In CITI, please complete the Researchers and Research Staff course. This must be completed by you and your staff. The training also provides extra safety guidance for working with hazardous materials that require BSL-2 containment.

**MOTION AND VOTE**: The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed the initial application at their full board meeting and determined that additional information or modifications are required. Total Members Voting: **7** [ For: **7** Absent: **0** Against: **0** Conflict of Interest: **0** Not Present: **0** Abstained: **0** ]

TTUHSC EP IBC Meeting Minutes - 08/19/2025

Page **1** of **2** 



# SUBMISSION OUTCOME: Additional Information Required

IBC# 25009 Full Renewal Expiration Date: 08/31/2028

Shilpa Singh, DDS BDS MS/TTUHSC El Paso - SOD - School of Dentistry

Biosafety Level: BSL 2

#### **ADMINISTRATIVE COMMENT:**

### Comment:

The PI has addressed the concerns of the reviewers. Stipulations were 1. In section 5.5 Please address who will transfer the saliva specimen from the clinic to the lab.

#### **MEMBER COMMENTS:**

### Comment:

MSB1 3015 does not appear to be designated or equipped as a BSL-2. Currently, a researcher is working in this location. Could the location indicated on the application be incorrect?

**RECOMMENDATIONS:** Approve

**MOTION AND VOTE**: The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed this protocol at their full board meeting and granted unrestricted approval.

Total Members Voting: 7 [ For: 7 Absent: 0 Against: 0 Conflict of Interest: 0 Not Present: 0 Abstained: 0 ]

SUBMISSION OUTCOME: Approved

IBC# 25009 Full Renewal Expiration Date:

Shilpa Singh, DDS BDS MS/TTUHSC El Paso - SOD - School of Dentistry

Biosafety Level: BSL 2

#### **ADMINISTRATIVE COMMENT:**

### Comment:

This is an Initial Application. The PI is requesting

Space: MSBI 3015 Chemicals: N/A

Biological Agents: Body Fluids

Biosafety Level: BSL2

Transport and hazardous shipper training will/ will not be required

This protocol does not involve recombinant or synthetic nucleic acid molecules. A notice was sent to the PI regarding pending LSE and On Campus training.

### **MEMBER COMMENTS:**

#### Comment:

Protocol adequately addresses the safety measures in process, but needs the following:

Please address who will transfer the saliva specimen from the clinic to the lab

If the lab is already approved for BSL 2, are the signs clearly posted?

# **Comment:**

Safety Services has the same comments as already mentioned regarding moving of specimens.

Additionally, MSB1 3015 does not look like it is set up or marked as BSL2. There is currently a researcher in this location. Could the location on application be incorrect?

**RECOMMENDATIONS:** Additional Information Required

**STIPULATIONS:** 1. In section 5.5 Please address who will transfer the saliva specimen from the clinic to the lab.

TTUHSC EP IBC Meeting Minutes - 08/19/2025

Page **1** of **2** 



2. MSB1 3015 does not appear to be designated or equipped as a BSL-2. Currently, a researcher is working in this location. Could the location indicated on the application be incorrect?

SUBMISSION OUTCOME: Additional Information Required

# **EXPEDITED REVIEW**

N/A

# ADMINISTRATIVE-ANNUAL STATUS REPORTS

IBC# 18008 Full Renewal Expiration Date: 08/31/2027

Marc Zuckerman, M.D./ Biosafety Level: BSL 2

# **ADMINISTRATIVE COMMENT:**

# **Comment:**

This is an Annual Status Report. COI, FD, and LSE are complete for the PI and staff. The study does include shipper and on-campus training. This training is complete for those listed in section 5.5 and 5.6. The biosafety level is 2. This protocol does not involve recombinant or synthetic nucleic acid molecules.

**RECOMMENDATIONS**: Acknowledge

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 24008 Full Renewal Expiration Date: 08/31/2027

Cynthia Perry, PhD/TTUHSC El Paso - SOM - Admissions

Biosafety Level: BSL 2

#### **ADMINISTRATIVE COMMENT:**

# **Comment:**

This is an Annual Status Report. COI, FD, and LSE are complete for the PI and staff. The study does not include shipper and on-campus training. The biosafety level is 2. This protocol does not involve recombinant or synthetic nucleic acid molecules.

**RECOMMENDATIONS**: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

# **ADMINISTRATIVE-AMENDMENTS**

IBC# 22009 Full Renewal Expiration Date: 08/31/2025

Jeana E. Barrow, DVM/TTUHSC El Paso - OR - LARC

Biosafety Level: BSL 2

#### **ADMINISTRATIVE COMMENT:**

#### Comment:

This is a personnel change to remove Frank Martinez who is no longer with the institution.

**RECOMMENDATIONS:** Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

TTUHSC EP IBC Meeting Minutes - 08/19/2025

Page **1** of **2** 



IBC# 18024 Full Renewal Expiration Date: 08/31/2026

Richard W McCallum, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

# **ADMINISTRATIVE COMMENT:**

**Comment:** 

This is a personnel change to remove Adriana Acosta who is no longer with the institution.

**RECOMMENDATIONS:** 1. Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

#### **TERMINATIONS**

N/A

#### **BSO REPORT**

There were no major deficiencies reported for the previous month.